PolyPeptide wins Malmö Life Science Business Award
28 Jun 2022 - Malmö, 21 June 2022 We are proud of our site in Malmö, Sweden, for winning the Life Science Business Award of the city (Malmö Näringslivspris Life […]
Read moreMonika Casanova joining PolyPeptide as CHRO and member of the PMC
9 May 2022 - Baar, 9 May 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that Monika Casanova has joined the Group […]
Read morePolyPeptide announces results of the annual General Meeting 2022
26 Apr 2022 - Zug, 26 April 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that the shareholders approved all proposals put […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2022
1 Apr 2022 - Zug, 1 April 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published today the invitation to its first annual […]
Read morePolyPeptide achieves strong profitable growth in 2021
15 Mar 2022 - Media Release – ad hoc announcement pursuant to Art. 53 LR PolyPeptide achieves strong profitable growth in 2021 Zug, 15 March 2022 – PolyPeptide Group […]
Read moreEfficient and sustainable solutions for large scale peptide manufacturing
22 Dec 2021 - We are happy to share the latest scientific publication from the PolyPeptide Innovation Team, Dr. Renan Revetti Duran, Innovation Scientist and Dr. Olivier Ludemann-Hombourger, Global Director, […]
Read morePolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
1 Dec 2021 - PolyPeptide Group / Key word(s): Personnel PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen […]
Read moreResults of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
10 Nov 2021 - PolyPeptide Group / Key word(s): Transaction in Own Shares Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG 10-Nov-2021 / 07:15 CET/CEST […]
Read morePolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement Zug, 1 September 2021 – PolyPeptide is pleased to announce that […]
Read more